TABLE I.
Immunologic studies
| Patient VI:5 | Patient VI:2 | Patient V:3 | Patient V:4 | Patient V:5 | |
|---|---|---|---|---|---|
| Serum immunoglobulins | |||||
| IgG (660-1350 mg/dL) | 1,760 | 1,330 | 200 | 218 | 419 |
| IgM (56-350 mg/dL) | 52 | 159 | 187 | 68 | 93 |
| IgA (70-312 mg/dL) | 79 | 332 | <22 | <35 | <0.93 |
| IgE (1.5-114 IU/mL) | 99 | 12.5 | <20 | ND | 22 |
| Lymphocytes (cells/μL) | |||||
| CD3+ cells (700-2100) | 2,700 (73%) | 1,575 (79%) | 823 (72%) | 1,089 (77%) | 1,557 (79%) |
| CD4+ cells (300-1400) | 1,290 (35%) | 941 (10%) | 342 (30%) | 596 (42%) | 1,060 (54%) |
| CD8+ cells (200-900) | 1,590 (43%) | 700 (35%) | 617 (54%) | 540 (38%) | 0.628 (32%) |
| CD19+ cells (100-500) | 520 (14%) | 200 (10%) | 91 (8%) | 43 (3%) | 196 (10%) |
| CD16/CD56+ cells (90-600) | 370 (10%) | 120 (6%) | 194 (17%) | 142 (10%) | 216 (11%) |
| Proliferation (cpm)* | |||||
| PHA patient (control subject) | 245,369 (128,631) | 193,826 (128,631) | 5,461 (53,398) | 9,594 (53,398) | 2,547 (53,398) |
| ConA patient (control subject) | 139,516 (97,565) | 109,047 (97,565) | ND | ND | ND |
| Anti-CD3 patient (control subject) | ND | ND | 22,683 (41,866) | 4,928 (41,866) | 3,550 (41,866) |
Values in parentheses are values for healthy adult control subjects. Percentages indicate the percentage of the individual subsets in the lymphocyte gate.
ND, Not done.
*
Measurement of T-cell proliferation for patients VI.5 and VI.2 was done in a different laboratory than measurement of proliferation for patients V.3, V.4, and V.5. The results of a healthy control subject examined the same day are shown in parentheses.